CN103655843A - Yikangbuyuan tablet, and preparation method and application thereof - Google Patents
Yikangbuyuan tablet, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103655843A CN103655843A CN201310670782.5A CN201310670782A CN103655843A CN 103655843 A CN103655843 A CN 103655843A CN 201310670782 A CN201310670782 A CN 201310670782A CN 103655843 A CN103655843 A CN 103655843A
- Authority
- CN
- China
- Prior art keywords
- preparation
- extraction
- yikang complement
- complement sheet
- sheet according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 238000000874 microwave-assisted extraction Methods 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims abstract description 7
- 208000032839 leukemia Diseases 0.000 claims abstract description 6
- 210000002540 macrophage Anatomy 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 230000000295 complement effect Effects 0.000 claims description 42
- 238000000605 extraction Methods 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 6
- 229940126678 chinese medicines Drugs 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 244000286838 Eclipta prostrata Species 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000007393 Magnolia hypolampra Species 0.000 abstract 1
- 241000736199 Paeonia Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 240000003582 Platycodon grandiflorus Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a preparation method and application of a Yikangbuyuan tablet. The Yikangbuyuan tablet is prepared from 280g of radix astragali, 80g of Michelia hedyosperma Lew, 190g of angelica, 220g of yerbadetajo, 190g of rhizoma atractylodis, 150g of safflower, 140g of red paeonia, 140g of peach kernel, 150g of radix achyranthis bidentatae, 120g of hemlock parsley, 70g of fructus aurantii and 100g of balloonflower by supercritical extraction and microwave extraction, so that the penoniflorin content is greatly enhanced. The invention also provides application of the Yikangbuyuan tablet in preparing medicines for inhibiting mouse mononuclear macrophage leukaemia cell RAW264.7 proliferation.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of preparation method and application of Yikang complement sheet.
Background technology
Yikang complement granule standard No. WS-10983(ZD-0983)-2002, be recorded in national standard for traditional Chinese medicines compilation internal medicine taste fascicle.By Radix Astragali 280g, fiber crops rare 80g, Radix Angelicae Sinensis 190g, Herba Ecliptae 220g, Rhizoma Atractylodis 190g, Flos Carthami 150g, Radix Paeoniae Rubra 140g, Semen Persicae 140g, Radix Achyranthis Bidentatae 150g, Rhizoma Chuanxiong 120g, Fructus Aurantii 70g, Radix Platycodonis 100g, as crude drug, made, there is benefiting QI for activating blood circulation, the effect of strengthening spleen, tonifying kidney.The spiritlessness and weakness causing for blood stasis due to qi deficiency, deficiency of spleen and stomach, short breath, insomnia, soreness of the waist and knees, the forgetful grade of lack of appetite disease.
In prior art, not yet have Yikang complement granule aspect extraction preparation, adopting the report of supercritical and microwave technology, and volatile oil extract, the method that decocting boils, technique is coarse, backward, and impurity is many, cause patient's consumption excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
In order to solve above-mentioned technical problem, the invention provides a kind of preparation method of Yikang complement sheet.
Another object of the present invention is to provide a kind of Yikang complement sheet to suppress the application in mouse monokaryon macrophage leukaemia RAW264.7 cell proliferation medicine in preparation.
The object of the invention is to realize by following scheme:
A kind of preparation method of Yikang complement sheet, by Radix Astragali 280g, fiber crops rare 80g, Radix Angelicae Sinensis 190g, Herba Ecliptae 220g, Rhizoma Atractylodis 190g, Flos Carthami 150g, Radix Paeoniae Rubra 140g, Semen Persicae 140g, Radix Achyranthis Bidentatae 150g, Rhizoma Chuanxiong 120g, Fructus Aurantii 70g, Radix Platycodonis 100g, as crude drug, made, described preparation method is comprised of the following step: get that fiber crops are rare, Radix Angelicae Sinensis, Rhizoma Atractylodis, Semen Persicae, Rhizoma Chuanxiong, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow 1-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extracts 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 300, every heavy 0.3g.
In the preparation method of above-mentioned Yikang complement sheet, described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
In the preparation method of above-mentioned Yikang complement sheet, described CO
2in supercritical extraction, extracting pressure is 25MPa.
In the preparation method of above-mentioned Yikang complement sheet, described CO
2in supercritical extraction, extraction temperature is 60 ℃.
In the preparation method of above-mentioned Yikang complement sheet, described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
In the preparation method of above-mentioned Yikang complement sheet, described CO
2in supercritical extraction, extraction time is 200min.
In the preparation method of above-mentioned Yikang complement sheet, described microwave extracting power is 700W.
In the preparation method of above-mentioned Yikang complement sheet, the each extraction time of described microwave extracting is 8 minutes.
Above-mentioned Yikang complement sheet suppresses the application in mouse monokaryon macrophage leukaemia RAW264.7 cell proliferation medicine in preparation.
In prior art, each 1 bag of Yikang complement granule, every bag of 7g, 3 times on the one.Yikang complement granule dosage is large, and granule preparation need to add a large amount of sugar, and diabetics is not suitable for, and the words taste of not sugaring is not good, and patient is not easy under clothes, and compliance is poor.The every heavy 0.3g of Yikang complement sheet that adopts the inventive method to be prepared into only needs 2 at every turn, within 1st, takes 3 times.Greatly reduced dose having under the condition of more active component.This conclusion can be by following evidence.And be prepared into tablet, patient swallows with water, dosage is little and without bitterness, patient is easy to accept.
The comparison of paeoniflorin content in Yikang complement sheet prepared by test one, distinct methods
1, instrument and reagent Yikang complement of the present invention sheet: press embodiment 1 method preparation, use 1510g crude drug, make 300 through extracting, every heavy 0.3g.Former Yikang complement granule, according to WS-10983(ZD-0983)-2002 standard method preparations.Agilent1200 high performance liquid chromatograph; METTLER AE240 electronic analytical balance; Peoniflorin reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
According to high performance liquid chromatography (appendix V D of Chinese Pharmacopoeia version in 2010), measure.
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Acetonitrile-0.2% phosphate aqueous solution (15: 85) is mobile phase; Detection wavelength is 230nm.Number of theoretical plate calculates and should be not less than 3000 by peoniflorin peak.
The preparation of the reference substance solution phosphorus pentoxide drying under reduced pressure peoniflorin reference substance of 36 hours of learning from else's experience is appropriate, accurately weighed, adds methanol and makes every 1ml containing the solution of 0.1mg, obtains.
Yikang complement sheet of the present invention is got in the preparation of product need testing solution of the present invention, and porphyrize, gets 2.25g, accurately weighed, to put in tool plug conical flask, precision adds the close plug of methanol 25ml., weighed weight, supersound process (power 250w. frequency 33kHz) 1 hour, lets cool, weighed weight again, the weight of supplying less loss with methanol, shakes up, and filters, with microporous filter membrane (0.45 μ m), filter, obtain.。
The Yikang complement granule of this contrast is got in the preparation of reference product need testing solution, and porphyrize, gets 2.5g, accurately weighed, to put in tool plug conical flask, precision adds the close plug of methanol 25ml., weighed weight, supersound process (power 250w. frequency 33kHz) 1 hour, lets cool, weighed weight again, the weight of supplying less loss with methanol, shakes up, and filters, with microporous filter membrane (0.45 μ m), filter, obtain.
Algoscopy is accurate reference substance solution and each 10 μ L of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
3, result
Result shows, in Yikang complement sheet of the present invention, the content of peoniflorin is 5-8mg/ sheet; And the content of peoniflorin is 4.8mg/ bag in former Yikang complement granule, each serving the paeoniflorin content of 2 of consumptions be former granule content 2-4 doubly, in the situation that dose reduces, paeoniflorin content improves a lot.
Above-mentioned research shows, the Yikang complement sheet that adopts preparation method of the present invention to prepare, active constituent content is far away higher than WS-10983(ZD-0983) the Yikang complement granule prepared of the method recorded of-2002 standards.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get Radix Astragali 280g, fiber crops rare 80g, Radix Angelicae Sinensis 190g, Herba Ecliptae 220g, Rhizoma Atractylodis 190g, Flos Carthami 150g, Radix Paeoniae Rubra 140g, Semen Persicae 140g, Radix Achyranthis Bidentatae 150g, Rhizoma Chuanxiong 120g, Fructus Aurantii 70g, Radix Platycodonis 100g, Jiang Mahan, Radix Angelicae Sinensis, Rhizoma Atractylodis, Semen Persicae, Rhizoma Chuanxiong join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, 40 ℃ of temperature, CO
2flow 2ml/g crude drug min, extraction time 200min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 700W, extracts 2 times, each 8 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 300, every heavy 0.3g.
After testing, in finished product, the content of peoniflorin is 7.8mg/ sheet.
Embodiment 2
Get Radix Astragali 280g, fiber crops rare 80g, Radix Angelicae Sinensis 190g, Herba Ecliptae 220g, Rhizoma Atractylodis 190g, Flos Carthami 150g, Radix Paeoniae Rubra 140g, Semen Persicae 140g, Radix Achyranthis Bidentatae 150g, Rhizoma Chuanxiong 120g, Fructus Aurantii 70g, Radix Platycodonis 100g, Jiang Mahan, Radix Angelicae Sinensis, Rhizoma Atractylodis, Semen Persicae, Rhizoma Chuanxiong join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 30MPa, temperature 50 C, CO
2flow 3ml/g crude drug min, extraction time 180min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600W, extracts 2 times, each 5 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 300, every heavy 0.3g.
After testing, in finished product, the content of peoniflorin is 5.6mg/ sheet.
Embodiment 3
Get Radix Astragali 280g, fiber crops rare 80g, Radix Angelicae Sinensis 190g, Herba Ecliptae 220g, Rhizoma Atractylodis 190g, Flos Carthami 150g, Radix Paeoniae Rubra 140g, Semen Persicae 140g, Radix Achyranthis Bidentatae 150g, Rhizoma Chuanxiong 120g, Fructus Aurantii 70g, Radix Platycodonis 100g, Jiang Mahan, Radix Angelicae Sinensis, Rhizoma Atractylodis, Semen Persicae, Rhizoma Chuanxiong join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 15MPa, 30 ℃ of temperature, CO
2flow 1ml/g crude drug min, extraction time 220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 800W, extracts 2 times, each 10 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 300, every heavy 0.3g.
After testing, in finished product, the content of peoniflorin is 6.2mg/ sheet.
Embodiment 4: Yikang complement sheet suppresses the experimentation data of mouse monokaryon macrophage leukaemia RAW264.7 cell proliferation
1. experiment material
1.1 experiment cell strains
Mouse monokaryon macrophage leukaemia RAW264.7 cell, Shandong University's laboratory cell bank, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: Yikang complement sheet of the present invention: press embodiment 1 method preparation.
Medicinal liquid liquid storage: take 100mg Yikang complement sheet, be dissolved in 5ml dehydrated alcohol, 0.2 μ m filter filters, 500 μ ldoff pipe subpackages ,-20 ℃ of storages, 0.2 μ m filter filters dehydrated alcohol in order to the use of matched group simultaneously.
1.3 experiment reagent
DMEM (Cat.No.12100-061Lot.No.758137 of GIBCO company); Hyclone (Lot.No.100419 of Tian Hang bio tech ltd, Zhejiang); NaHCO
3(Cat.No.11810-033Lot.No.1088387 of Shanghai Jiu Yi chemical reagent company limited); Trypsin(AMRESCO company); EDTA(AMRESCO company); Penicillin G Sodium Salt(AMRESCO company 1); Streptomycin Sulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): the autogamy of PBS(laboratory);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DMIL); Visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX190); CO
2incubator (FORMA model: 3111); (safe and sound company of Su Jing group manufactures model to super-clean bench: SW-CJ-ZFD); Pure water instrument (U.S. Sprlng company model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai accurate experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) RAW264.7 cell uses DMEM+10%FBS in 37 ℃, 5%CO
2carry out cellar culture (10cm culture dish), when Growth of Cells is during to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 ℃ of digestion 2min, add wherein 5ml complete medium neutralization reaction, after piping and druming cell, proceeded in centrifuge tube, the centrifugal 5min of 1000rpm, adjusts concentration of cell suspension 3 * 10
4individual/ml.
2) cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 ℃, 5%CO
2) cellar culture.
3) according to Growth of Cells situation, generally grow to 50%-70%, add Yikang complement sheet solution, continue to cultivate 24h.
4) after 24h, add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT), continue to cultivate 4h.
5) after 4h, buckle method is removed supernatant, with absorbent paper, pats dry gently, and low-speed oscillation 10min on shaking table, as entered 200 μ l dimethyl sulfoxide, is put in every hole, and crystal is fully dissolved.At enzyme-linked immunosorbent assay instrument 490nm place, measure the light absorption value in each hole.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), sets 6 multiple holes for every group.
7) result represents the suppression ratio of cell with medicine: cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value * 100%.Experiment repeats 3 times.
3. statistical disposition
Adopt correlation analysis and Student t check in Microsoft Excel2007 software, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, with matched group comparison, when dosage reaches 5mg/ml, to RAW264.7 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has utmost point significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 1 Yikang complement sheet is on RAW264.7 cell inhibitory effect impact research (X ± SD)
| Group | Drug level (mg/ml) | Suppression ratio (%) |
| Matched group | 0 | 0 |
| 1 | 5 | 10.80±10.02 |
| 2 | 10 | 22.36±12.77* |
| 3 | 15 | 35.41±16.92** |
| 4 | 20 | 43.62±15.32** |
Note: with matched group comparison, * P<0.01; * P<0.001.
5. experiment conclusion
Yikang complement sheet can suppress RAW264.7 cell proliferation, reduces the Growth of Cells number of RAW264.7 cell, and this effect is dose dependent.
Claims (9)
1. the preparation method of a Yikang complement sheet, by Radix Astragali 280g, fiber crops rare 80g, Radix Angelicae Sinensis 190g, Herba Ecliptae 220g, Rhizoma Atractylodis 190g, Flos Carthami 150g, Radix Paeoniae Rubra 140g, Semen Persicae 140g, Radix Achyranthis Bidentatae 150g, Rhizoma Chuanxiong 120g, Fructus Aurantii 70g, Radix Platycodonis 100g, as crude drug, made, it is characterized in that, described preparation method is comprised of the following step: get that fiber crops are rare, Radix Angelicae Sinensis, Rhizoma Atractylodis, Semen Persicae, Rhizoma Chuanxiong, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow 1-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extracts 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 300, every heavy 0.3g.
2. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
3. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, described CO
2in supercritical extraction, extracting pressure is 25MPa.
4. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, described CO
2in supercritical extraction, extraction temperature is 60 ℃.
5. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
6. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, described CO
2in supercritical extraction, extraction time is 200min.
7. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, described microwave extracting power is 700W.
8. the preparation method of Yikang complement sheet according to claim 1, is characterized in that, the each extraction time of described microwave extracting is 8 minutes.
9. Yikang complement sheet claimed in claim 1 suppresses the application in mouse monokaryon macrophage leukaemia RAW264.7 cell proliferation medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310670782.5A CN103655843B (en) | 2013-12-11 | 2013-12-11 | A kind of Yikang complement sheet and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310670782.5A CN103655843B (en) | 2013-12-11 | 2013-12-11 | A kind of Yikang complement sheet and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103655843A true CN103655843A (en) | 2014-03-26 |
| CN103655843B CN103655843B (en) | 2016-01-27 |
Family
ID=50295402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310670782.5A Expired - Fee Related CN103655843B (en) | 2013-12-11 | 2013-12-11 | A kind of Yikang complement sheet and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655843B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306825A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of leukemia cell L1210 cell |
| CN104306826A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of leukemia cell L6565 cell |
| CN104306820A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of lung cancer cell LLC cell |
| CN104306829A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparing method of rhubarb and day lily liver tonifying tablet and application thereof in preparation of drugs for inhibiting cell proliferation of anus sarcoma cells S-180 |
| CN104306824A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparing method of rhubarb and day lily liver tonifying tablet and application thereof in preparation of drugs for inhibiting cell proliferation of liver cancer cells Hepa1-6 |
| CN104306823A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of breast tumor cell C127 cell |
| CN104324288A (en) * | 2014-11-13 | 2015-02-04 | 山东中大药业有限公司 | Preparation method of Huangxuan liver-benefiting tablets and application of Huangxuan liver-benefiting tablets in preparing medicaments for inhibiting cell proliferation of embryonic carcinoma cells F9 |
| CN104324289A (en) * | 2014-11-13 | 2015-02-04 | 山东中大药业有限公司 | Preparation method of Huangxuan liver-benefiting tablets and application of Huangxuan liver-benefiting tablets in preparing medicament for inhibiting cell proliferation of lymphoma cells EL4 |
| CN104383380A (en) * | 2014-11-13 | 2015-03-04 | 山东中大药业有限公司 | Preparation method of dock root and hemerocallis fulva liver tonifying tablets and application of dock root and hemerocallis fulva liver tonifying tablets to preparation of medicines for inhibiting proliferation of prostate cancer cell RM-1 |
| CN104435912A (en) * | 2014-11-13 | 2015-03-25 | 山东中大药业有限公司 | Preparation method of rumex nepalensis and hemerocallis tablet for benefiting liver and application of rumex nepalensis and hemerocallis tablet to preparation of drug for inhibiting proliferation of ascetic tumor cell SAC-IIC3 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072813A1 (en) * | 1999-12-29 | 2003-04-17 | Huiping Zhao | Composition and method for the treatment of vitiligo |
| CN1961929A (en) * | 2005-11-09 | 2007-05-16 | 北京奇源益德药物研究所 | 'Yi Kang Bu Yuan' formulation for benefiting qi, moving blood, invigorating spleen and tonifying kidney, its preparation method and quality control method |
| CN102988526A (en) * | 2012-10-08 | 2013-03-27 | 卞毓平 | Method for preparing Bailing tablets and application |
| CN103655842A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell EL4. IL-2 proliferation |
| CN103655841A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphoid cancer cell P388D1 proliferation |
-
2013
- 2013-12-11 CN CN201310670782.5A patent/CN103655843B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072813A1 (en) * | 1999-12-29 | 2003-04-17 | Huiping Zhao | Composition and method for the treatment of vitiligo |
| CN1961929A (en) * | 2005-11-09 | 2007-05-16 | 北京奇源益德药物研究所 | 'Yi Kang Bu Yuan' formulation for benefiting qi, moving blood, invigorating spleen and tonifying kidney, its preparation method and quality control method |
| CN102988526A (en) * | 2012-10-08 | 2013-03-27 | 卞毓平 | Method for preparing Bailing tablets and application |
| CN103655842A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell EL4. IL-2 proliferation |
| CN103655841A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphoid cancer cell P388D1 proliferation |
Non-Patent Citations (3)
| Title |
|---|
| CATHY WEN CHUAN BI, ET AL: "Fo Shou San, an Ancient Herbal Decoction Prepared from Rhizoma Chuanxiong and Radix Angelicae Sinensis, Stimulates the Production of Hemoglobin and Erythropoietin in Cultured Cells", 《PLANTA MED》 * |
| L.H. HUANG, ET AL: "Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells", 《CELL PROLIFERATION》 * |
| MIN HO HAN, ET AL: "Citrus aurantium L.exhibits apoptotic effects on U937 human leukemia cells partly through inhibition of Akt", 《INTERNATIONAL JOURNAL OF ONCOLOGY》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306825A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of leukemia cell L1210 cell |
| CN104306826A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of leukemia cell L6565 cell |
| CN104306820A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of lung cancer cell LLC cell |
| CN104306829A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparing method of rhubarb and day lily liver tonifying tablet and application thereof in preparation of drugs for inhibiting cell proliferation of anus sarcoma cells S-180 |
| CN104306824A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparing method of rhubarb and day lily liver tonifying tablet and application thereof in preparation of drugs for inhibiting cell proliferation of liver cancer cells Hepa1-6 |
| CN104306823A (en) * | 2014-11-13 | 2015-01-28 | 山东中大药业有限公司 | Preparation method of liver benefiting tablet containing nepal dock root and day lily and application of liver benefiting tablet to preparation of drug for restraining multiplication of breast tumor cell C127 cell |
| CN104324288A (en) * | 2014-11-13 | 2015-02-04 | 山东中大药业有限公司 | Preparation method of Huangxuan liver-benefiting tablets and application of Huangxuan liver-benefiting tablets in preparing medicaments for inhibiting cell proliferation of embryonic carcinoma cells F9 |
| CN104324289A (en) * | 2014-11-13 | 2015-02-04 | 山东中大药业有限公司 | Preparation method of Huangxuan liver-benefiting tablets and application of Huangxuan liver-benefiting tablets in preparing medicament for inhibiting cell proliferation of lymphoma cells EL4 |
| CN104383380A (en) * | 2014-11-13 | 2015-03-04 | 山东中大药业有限公司 | Preparation method of dock root and hemerocallis fulva liver tonifying tablets and application of dock root and hemerocallis fulva liver tonifying tablets to preparation of medicines for inhibiting proliferation of prostate cancer cell RM-1 |
| CN104435912A (en) * | 2014-11-13 | 2015-03-25 | 山东中大药业有限公司 | Preparation method of rumex nepalensis and hemerocallis tablet for benefiting liver and application of rumex nepalensis and hemerocallis tablet to preparation of drug for inhibiting proliferation of ascetic tumor cell SAC-IIC3 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103655843B (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690646B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicine for inhibiting mouse lymphoma cell YAC-1 cell proliferation | |
| CN103655843B (en) | A kind of Yikang complement sheet and its preparation method and application | |
| CN103656493B (en) | A kind of preparation method of blood stasis dispelling stomach reinforcing sheet and application | |
| CN103638450B (en) | A kind of preparation method of Muxiangliqi Tablet and application | |
| CN103690647B (en) | A kind of preparation method of Yikang complement sheet and the application in suppression mouse leukemia cell L6565 cell proliferation thereof | |
| CN103655839B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lung cancer cell LLC proliferation | |
| CN103655842B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell EL4. IL-2 proliferation | |
| CN103655841B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphoid cancer cell P388D1 proliferation | |
| CN103800498A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting mouse prostate cancer cell RM-1 from cell proliferation | |
| CN103751424A (en) | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. | |
| CN103768211A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lymphomata cell EL4 from cell proliferation | |
| CN103800818A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell FO from cell proliferation | |
| CN103768266A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting mouse leukaemia cell L6565 from cell proliferation | |
| CN103800499A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting melanoma cell B16 from cell proliferation | |
| CN103735960A (en) | Application of boenninghausenia sessilicarpa cough-asthma tablet to prepare medicaments for inhibiting lung cancer cell LLC proliferation | |
| CN103768267A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell H22 from cell proliferation | |
| CN103655840B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse leukaemia cell L1210 proliferation | |
| CN103655838B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell L5178Y proliferation | |
| CN103800871A (en) | Application of dizziness-relieving and calming tablet in preparing medicine for inhibiting cell proliferation of embryonal carcinoma cell F9 | |
| CN103751425A (en) | Preparation method of Qingmei cold-treatment tablet and use of Qingmei cold-treatment tablet in drug for inhibiting breast tumor cell C127 proliferation | |
| CN103768207A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell Hepa1-6 from cell proliferation | |
| CN103800770A (en) | Application of boenninghausenia cough tablet in preparing medicine for inhibiting cell proliferation of breast tumor cell C127 | |
| CN103768265A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell LLC from cell proliferation | |
| CN103768264A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting teratoma cell P19 from cell proliferation | |
| CN103768514A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell SP2/0 from cell proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Dong Guangcai Inventor after: Tian Jun Inventor before: Wei Shutong Inventor before: Duan Xuewen |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160104 Address after: 262100, No. 1, building 11, building 265, 502 Xingan Road, Anqiu, Shandong, Weifang Applicant after: Dong Guangcai Address before: 250062, No. ten, No. 16369, Lixia District, Ji'nan City, Shandong Province Applicant before: SHANDONG ZHONGDA PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160127 Termination date: 20161211 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |